januvia a glp 1 vs Ozempic Sitagliptin - an overview |

Amruta Prabhu +2 more Table of Contents Introduction Diabetes continues to be a major public health concern in India

Both formulations are administered as intramuscular injections, usually weekly, as part of a medically-supervised weight loss protocol that includes caloric restriction and, increasingly, GLP-1 receptor agonist therapy like semaglutide or tirzepatide

IGF-1 LR3 + CJC-1295 (no DAC) + Ipamorelin A three-peptide "full GH/IGF-1 axis" stack meant to hit the same growth-signaling pathway from two directions at once: CJC-1295 + Ipamorelin are reported to drive a bigger, more frequent pulse of the body's own growth hormone (and the downstream IGF-1 rise that follows it), while IGF-1 LR3 is injected directly to activate IGF-1 receptors in trained muscle immediately, without waiting on the GH step though no trial has tested this exact three-peptide stack

This is increasingly important as more trials move into decentralized, at-home settings without clinical supervision, where patients must rely on the device design and labelling to use it correctly